The National Diabetes Audit (NDA) provides a comprehensive view of diabetes care in England and Wales. It measures the effectiveness of diabetes healthcare against National Institute for Health and Care Excellence (NICE) Clinical Guidelines and NICE Quality Standards. This NICE guidance is based on evidence that regular systematic review of people with diabetes and achievement of glucose, blood pressure and cardiovascular risk standards maintains health and reduces long term complications.

The National Diabetes Audit (NDA) is part of the National Clinical Audit and Patient Outcomes Programme (NCAPOP) which is commissioned by the Healthcare Quality Improvement Partnership (HQIP) and funded by NHS England. The NDA is managed by NHS Digital in partnership with Diabetes UK. The NDA measures the effectiveness of diabetes healthcare against NICE Clinical Guidelines and NICE Quality Standards, in England and Wales. The NDA collects and analyses data for use by a range of stakeholders to drive changes and improvements in the quality of services and health outcomes for people with diabetes. This report details the findings and recommendations relating to diabetes care process completion, treatment target achievement and structured education for the 2018-19 audit. The audit collected data during May and June 2019, for the period 01 January 2018 to 31 March 2019. This report follows the NDA short report publication in December 2019, which provided the top level findings for the 2018-19 audit, along with local level data made available to services in a timely manner that can help drive improvements in the quality of diabetes care locally. A new method of collecting structured education attendance data was trialled for 2018-19. In addition to extracting education data from GP practice systems, structured education providers could submit data directly via the Clinical Audit Platform (CAP). Around 20 providers submitted, however only a small proportion of records were submitted with the required data. This exercise has shown the potential value of this additional collection and improvements to the process are being developed to improve future collections. Included within this publication is the National Diabetes Insulin Pump Audit interactive reporting and supporting information. It provides information on people with Type 1 diabetes on an insulin pump at National, LHB, and Specialist Diabetes Service level for the 2018-19 audit period. Note: An error was identified in the original release of the National Diabetes Insulin Pump Audit 2018-19, Interactive Report for Specialist Services in England. The number of people with Type 1 diabetes in the 'HbA1c values' section was overstated and showed the total number of people with any type of diabetes seen at the service. This has been corrected and replaced with a new version of the report on 23 December 2020.

The National Diabetes Register was introduced in 2016 by the amendment of Act No. 372/2011 Coll. , on health services and conditions of their provision (Act on Health Services), by Act No. 147/2016 Coll. with effect from 1 July 2016.

It is a new type of register that uses as much as possible already existing data in the healthcare sector, namely the data of the National Register of Reimbursed Health Services (NRHZS), i.e. the administrative data of health insurance companies supplemented by data from laboratories that already exist in their information systems and data collection from nursing staff physicians involved in a referral network of providers or in planned observational studies.

Risk and prognostic factors of the disease, data related to the disease and its treatment, personal and family history of the patient related to the disease, including classification of the type and state of diabetes and laboratory values, provision of dispensary care are processed in the register; data needed to identify the provider diagnosing, treating and providing dispensary care.

The basic statistical unit of the record in the register is the record of diabetes.

The register provides an overview of a population-relevant disease from the point of view of epidemiology, treatment and control of diabetes at a hitherto inaccessible detailed level with minimal effort, as it is mostly the use of already existing data.

Mandatory duties and irreplaceable functions of the register:

• Monitoring the epidemiology of diabetes and its treatment as a socially extremely serious disease affecting a significant part of the population
• Monitoring the quality and outcomes of diabetes care
• Data reporting for EUROSTAT, WHO, OECD databases

The worksheets include data for all ICBs and GP practices in England within the May 2025 extraction of NDA data (April 2024 to March 2025 data). These data undergo further validation processes at the end of each audit year when data from specialist services are added in, at which point the data are considered to comprise the full annual dataset to be used in the annual NDA publications. Data for Local Health Boards (LHBs) in Wales and specialist diabetes services in England are not included in the quarterly publications. Their 2024-25 data (for the full audit period April 2024 to March 2025) will be extracted as part of the final NDA 2024-25 collection and reported in the NDA 2024-25 full audit period data release, scheduled for late 2025. Disclosure control has been applied to mitigate the risk of patient identification. Zeros are reported, and all numbers are rounded to the nearest 5, unless the number is 1 to 7, in which case it is rounded to ‘5’. This allows for more granular data to be made available, and also for data for all GP practices to be made available. Percentages where the denominator is less than or equal to 20 are not reliable and have therefore not been calculated in this release.

The National Diabetes Audit (NDA) is part of the National Clinical Audit and Patient Outcomes Programme (NCAPOP) which is commissioned by the Healthcare Quality Improvement Partnership (HQIP) and funded and managed by NHS England, in partnership with Diabetes UK. The NDA provides a comprehensive view of diabetes care in England and Wales. It measures the effectiveness of diabetes healthcare against National Institute for Health and Care Excellence (NICE) Clinical Guidelines and NICE Quality Standards. The NDA supports improvement in the quality of diabetes care by enabling participating NHS services and organisations to: Assess local practice against NICE guidelines. Compare their care, and care outcomes, with similar services and organisations, identify gaps or shortfalls that are priorities for improvement, identify and share best practice and provide a comprehensive national picture of diabetes care and outcomes in England and Wales. This data release includes the care process and treatment target measurements for the full 2023-24 audit period (1 January 2023 – 31 March 2024); presented for England primary care, Wales primary care and specialist services (hospital-based care), each with its own separate data file. Data from primary care in England was collected throughout the audit period. Data for specialist services in England is submitted throughout the year with the January 2023 to March 2024 cut of this data being taken in May 2024. Data from Wales was received in June 2024.

It was estimated that as of 2023, around **** million people in the United States had been diagnosed with diabetes. The number of people diagnosed with diabetes in the U.S. has increased in recent years and the disease is now a major health issue. Diabetes is now the seventh leading cause of death in the United States, accounting for ******percent of all deaths. What is prediabetes? A person is considered to have prediabetes if their blood sugar levels are higher than normal but not high enough to be diagnosed with type 2 diabetes. As of 2021, it was estimated that around ** million men and ** million women in the United States had prediabetes. However, according to the CDC, around ** percent of these people do not know they have this condition. Not only does prediabetes increase the risk of developing type 2 diabetes, but also increases the risk of heart disease and stroke. The states with the highest share of adults who had ever been told they have prediabetes are California, Hawaii, and New Mexico. The prevalence of diabetes in the United States As of 2023, around *** percent of adults in the United States had been diagnosed with diabetes, an increase from ****percent in the year 2000. Diabetes is much more common among older adults, with around ** percent of those aged 60 years and older diagnosed with diabetes, compared to just ****percent of those aged 20 to 39 years. The states with the highest prevalence of diabetes among adults are West Virginia, Mississippi, and Louisiana, while Utah and Colorado report the lowest rates. In West Virginia, around ** percent of adults have been diagnosed with diabetes.

The National Diabetes Audit (NDA) continues to provide a comprehensive view of Diabetes Care in England and Wales and measures the effectiveness of diabetes healthcare against NICE Clinical Guidelines and NICE Quality Standards, in England and Wales. This national report presents the key findings and recommendations on care processes and treatment target achievement rates from 2015-2016 in all age groups in England and Wales along with information on offers and attendance for structured education places. This year, for the first time information is reported on the number of people with diabetes who also have a learning disability and completion of care processes and treatment target achievement. A separate national report presents the key findings and recommendations; The Learning Disability - Supplementary Information report has also been developed as a power point presentation. As with last year's publication the main report contains information on the national key findings and recommendations and has also been developed as a power point presentation, along with slides highlighting the national findings there is also space to allow the incorporation of locally produced slides using the tables and charts from the interactive spreadsheets. We hope that users will find this beneficial to help disseminate the results of the audit locally. Supplementary data for England and Wales are contained in the excel spreadsheets. There are 6 excel spreadsheets; two spreadsheets contains the tables and charts in the national report and learning disability report along with some supplementary national figures, a further spreadsheet provides all 8 care process completion and all 3 treatment target achievement for CCGs/LHBs by age group. There are also 3 interactive excel spreadsheets which allow users to select the CCG/GP practice (England only), Local Health Board (Wales only) or Secondary Care Service (England only) of choice, information for the chosen site is then displayed in tables and charts. Please note that the interactive excel spreadsheets are large files (approximately 12MB) and may take some time to open. This report was updated on 09/02/17. The following amendments have been made to the report: The CCG/GP spreadsheet was updated as some of the CCGs/general practices were not available in the interactive aspect. We have also added a reference table for practice codes and names. All the data for care processes and treatment targets was correct in the supporting data tables. The spreadsheet report for Wales and LHBs has been amended. A practice wrongly appeared in a LHB, this practice has now been assigned to the correct LHB which has changed the results for LHB 7A2 and 7A3. The specialist service spreadsheet has been updated as the interactive aspect was not working for all hospitals. This does not change the results for specialist services. Both the CCG/GP and LHB spreadsheets have been updated for structured education offered and attendance. This has changed the results for individual CCGs/Practices and LHBs but not the national results. We have updated the methodology documentation for structured education to explain more fully how we have analysed and reported on the structured education data for the 2015-16 audit report. We have also added a link, which can be found below in resources, to our interactive dashboard for the 2015-16 report. This dashboard provides CCGs, LHBs and GPs (England only) with an alternative way to view their data for completion of all 8 care process and achievement of all 3 treatment targets as well their data on registrations by age, sex, deprivation and ethnicity.

The National Diabetes Insulin Pump Audit is part of the National Diabetes Audit (NDA). The National Diabetes Insulin Pump Audit collects information on the number and characteristics of people with Type 1 diabetes using an insulin pump, the reasons for going on an insulin pump and the outcomes achieved since starting on the pump. Making clinical audit data transparent In his transparency and open data letter to Cabinet Ministers on 7 July 2011, the Prime Minister made a commitment to make clinical audit data available from the national audits within the National Clinical Audit and Patient Outcomes Programme. What information is being made available? National Diabetes Insulin Pump Audit data for 2017-18 is available at England and Wales, Local Health Board (LHB) and Specialist Diabetes Service level for:

The National Diabetes Insulin Pump Audit is part of the National Diabetes Audit (NDA).

The National Diabetes Insulin Pump Audit collects information on the number and characteristics of people with Type 1 diabetes using an insulin pump, the reasons for going on an insulin pump and the outcomes achieved since starting on the pump.

Making clinical audit data transparent

In his transparency and open data letter to Cabinet Ministers on 7 July 2011, the Prime Minister made a commitment to make clinical audit data available from the national audits within the National Clinical Audit and Patient Outcomes Programme.

What information is being made available?

National Diabetes Insulin Pump Audit data for 2016-17 is available at England and Wales, Local Health Board (LHB) and Specialist Diabetes Service level for:

• Participation
• Patient demographics
• Prevalence
• Care process completion
• Treatment targets
• Diabetes characteristics

Using and interpreting the data

Data from the National Diabetes Insulin Pump Audit should not be looked at in isolation when assessing standards of care.

Accessing the data

The data are being made available on the data.gov website. Local Health Boards and Specialist Diabetes Services are identified by organisation code.

What does the data cover?

The audit looks at the following areas:

• Reason for starting on an insulin pump
• Care processes
• Treatment targets
• Structured Education

What period does the data cover?

This data covers the top level findings from the 2016-17 National Diabetes Insulin Pump Audit for the period 1 January 2016 to 31 March 2017. This National Report was published on 14 June 2018.

The information available from this webpage comes from the National Diabetes Audit - Diabetes Prevention Programme report.

The NHS Diabetes Prevention Programme (NHS DPP) is a joint commitment from NHS England, Public Health England and Diabetes UK to deliver, at scale, evidence based behavioural interventions that can prevent or delay the onset of Type 2 diabetes in adults who have been identified as having non-diabetic hyperglycaemia.

This report uses data collected alongside the National Diabetes Audit (NDA) for the period January 2017 to March 2018 inclusive.

This report is for England only. Unlike the NDA, it does not include information on Wales.

Making clinical audit data transparent

In his transparency and open data letter to Cabinet Ministers on 7 July 2011, the Prime Minister made a commitment to make clinical audit data available from the national audits within the National Clinical Audit and Patient Outcomes Programme.

What information is being made available?

National Diabetes Audit - Diabetes Prevention Programme data for 2017-18 is available at England, Clinical Commissioning Group (CCG) and GP practice-level for:

• Patient list size
• Patient demographics
• Diabetes characteristics
• Diabetes Prevention Programme take-up

These data do not list individual patient information nor do they contain any patient identifiable data.

Using and interpreting the data

Data from the National Diabetes Audit - Diabetes Prevention Programme should not be looked at in isolation when assessing standards of care.

Accessing the data

The data are being made available on the data.gov website. Each year a data file from the National Diabetes Audit - Diabetes Prevention Programme will be made available in CSV format. Hospitals are identified by name and their national code.

What does the data cover?

The audit looks at the following areas:

• Registrations and prevalence
• Offers of DPP
• Demographics

What period does the data cover?

This report covers data collected alongside the National Diabetes Audit (NDA) for the period January 2017 to March 2018 inclusive. The audit report was published on 11 July 2019.

North America Insulin Syringe Market size was valued at USD 259 Million in 2024 and is projected to reach USD 290 Million by 2032, growing at a CAGR of 1.7% from 2025 to 2032.

Key Market Drivers:

Increasing Diabetes Prevalence: According to the Centers for Disease Control and Prevention's (CDC) 2022 National Diabetes Statistics Report, more than 37.3 million Americans (or 11.3% of the US population) have diabetes, with roughly 28.7 million diagnosed and 8.5 million undiagnosed. The number of individuals diagnosed with diabetes has more than quadrupled over the previous 20 years, resulting in a significant and rising need for insulin syringes.

Ageing Population Growth: According to the United States Census Bureau, the number of Americans aged 65 and over is expected to reach 77 million in 2034. This age change is especially relevant for the insulin syringe industry, as type 2 diabetes is more common in older persons.

North America Sulfonylureas Market size was valued at USD 3.1 Billion in 2024 and is Projected to reach USD 3.9 Billion by 2032, growing at a CAGR of 1.9% from 2025 to 2032.

Key Market Drivers:

Increasing Prevalence of Type 2 Diabetes: According to the Centers for Disease Control and Prevention's (CDC) National Diabetes Statistics Report, approximately 37.3 million Americans (11.3% of the population) had diabetes in 2020, with Type 2 diabetes accounting for 90-95% of cases. This high incidence increases demand for sulfonylureas, which are still one of the most commonly recommended second-line treatments for Type 2 diabetes.

Cost-Effectiveness in Relation to Newer Medications: Sulfonylureas are far more cheap than modern diabetes treatments. According to a research published in the Journal of the American Medical Association (JAMA), the average monthly cost of sulfonylureas was $4-11, whereas newer GLP-1 receptor agonists cost $350-500.

The National Diabetes Audit (NDA) provides a comprehensive view of diabetes care in England and Wales and measures the effectiveness of diabetes healthcare against NICE Clinical Guidelines and NICE Quality Standards. Making clinical audit data transparent In his transparency and open data letter to Cabinet Ministers on 7 July 2011, the Prime Minister made a commitment to make clinical audit data available from the national audits within the National Clinical Audit and Patient Outcomes Programme. What information is being made available? National Diabetes Audit data for 2017-18 is available at England and Wales, Clinical Commissioning Group (CCG), Local Health Board (LHB), English GP practice and Specialist Diabetes Service level for: * Participation * Patient demographics * Diabetes characteristics * Structured Education offers These data do not list individual patient information nor do they contain any patient identifiable data. Using and interpreting the data Data from the National Diabetes Audit should not be looked at in isolation when assessing standards of care. Accessing the data The data are being made available on the data.gov website. GP practices and CCGs/LHBs are identified by organisation code. What does the data cover? The audit looks at the following areas: * Care processes * Treatment targets * Structured Education What period does the data cover? This data covers the top level findings from the 2017-18 National Diabetes Audit for the period 1 January 2017 to 31 March 2018. This National Report was published on 13 June 2019.

The National Diabetes Audit (NDA) provides a comprehensive view of diabetes care in England and Wales. It measures the effectiveness of diabetes healthcare against NICE Clinical Guidelines and NICE Quality Standards. This is the Type 1 Diabetes report. It details the findings and recommendations relating to diabetes care process completion, treatment target achievement and structured education for people with type 1 diabetes. The 2019-20 audit covers the period 01 January 2019 to 31 March 2020. This is the first NDA report dedicated to people with type 1 diabetes. A new diagnosis validation process, which considers medication as well as recorded diagnosis, has been introduced to try to ensure that only people with true type 1 diabetes are included (see appendix). Results are to be taken in the context of low data submission from specialist services, possibly hampered due to COVID-19.

The information available from this webpage comes from the National Diabetes Inpatient Audit. The National Diabetes Inpatient Audit is a snapshot audit of diabetes inpatient care.

During September 2019, hospitals across England collected data on the characteristics of the hospital, including participation, staffing levels and care improvement initiatives. Wales did not participate in NaDIA 2019.

Making clinical audit data transparent

In his transparency and open data letter to Cabinet Ministers on 7 July 2011, the Prime Minister made a commitment to make clinical audit data available from the national audits within the National Clinical Audit and Patient Outcomes Programme.

What information is being made available?

National Diabetes Inpatient Audit data for 2019 is available at hospital site level for:

• Audit participation and data completeness for the key fields
• Measures about the process of care given to patients
• Information about care outcomes and treatment.

These data do not list individual patient information nor do they contain any patient identifiable data.

Using and interpreting the data

Data from the National Diabetes Inpatient Audit should not be looked at in isolation when assessing standards of care.

Accessing the data

The data are being made available on the data.gov website. Each year a data file from the National Diabetes Inpatient Audit will be made available in CSV format. Hospitals are identified by name and their national code.

What period does the data cover?

This report covers hospital characteristics during September 2019. The audit report was published on 13 November 2020. Historic data is available for previous audit years (2010-2013, 2015-2017) where survey questions were comparable.

According to Cognitive Market Research, the global Insulin Pumps Market size will be USD 6251.8 million in 2025. It will expand at a compound annual growth rate (CAGR) of 9.00% from 2025 to 2033.

North America held the major market share for more than 37% of the global revenue with a market size of USD 2313.17 million in 2025 and will grow at a compound annual growth rate (CAGR) of 6.8% from 2025 to 2033.
Europe accounted for a market share of over 29% of the global revenue with a market size of USD 1813.02 million.
APAC held a market share of around 24% of the global revenue with a market size of USD 1500.43 million in 2025 and will grow at a compound annual growth rate (CAGR) of 11.0% from 2025 to 2033.
South America has a market share of more than 3.8% of the global revenue with a market size of USD 237.57 million in 2025 and will grow at a compound annual growth rate (CAGR) of 8.0% from 2025 to 2033.
Middle East had a market share of around 4% of the global revenue and was estimated at a market size of USD 250.07 million in 2025 and will grow at a compound annual growth rate (CAGR) of 8.3% from 2025 to 2033.
Africa had a market share of around 2.20% of the global revenue and was estimated at a market size of USD 137.54 million in 2025 and will grow at a compound annual growth rate (CAGR) of 8.7% from 2025 to 2033.
Smart insulin pumps category is the fastest growing segment of the Insulin Pumps Market

Market Dynamics of Insulin Pumps Market

Key Drivers for Insulin Pumps Market

Rising Diabetes Prevalence Boosting Insulin Pump Adoption to Boost Market Growth

Based on the Centers for Disease Control and Prevention (CDC), the prevalence of Americans diagnosed with diabetes has increased significantly, with more than 38.4 million individuals in the United States reported to have diabetes in 2021, and around 1.6 million Americans with Type 1 diabetes, the major population that uses insulin pumps. The growing incidence of Type 1 and insulin-dependent Type 2 diabetes has greatly increased the potential user population for insulin pumps. They provide accurate insulin delivery, enhanced glycemic control, and fewer episodes of hypoglycemia, making them a choice for long-term management of diabetes. The CDC's National Diabetes Statistics Report indicates the increasing population of diabetics, especially among children and youths, is promoting early and sophisticated treatment alternatives such as insulin pumps. Therefore, public health efforts also emphasize patient education on pioneering technologies, which indirectly contribute to market growth. The correlation between government-reported diabetes figures and rising medical technology use mirrors the dominant role played by public health information in shaping demand for insulin pumps.

https://www.cdc.gov/diabetes/php/data-research/methods.html?CDC_AAref_Val=https://www.cdc.gov/diabetes/data/statistics-report/index.html

Government Initiatives to Improve Diabetes Management Infrastructure Fueling Insulin Pump Market Growth

Government authorities around the world are actively developing healthcare infrastructure and providing funding to diabetes care programs, which largely boosts the growth of the insulin pumps market. For example, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the U.S. Department of Health and Human Services (HHS) has been investing in developing cutting-edge research and technology in diabetes management. Programs like the Special Statutory Funding Program for Type 1 Diabetes Research center on developing artificial pancreas systems and enhancing insulin delivery technologies. These programs not only subsidize R&D but also enhance awareness and availability of advanced treatment modalities such as insulin pumps. Furthermore, the Centers for Medicare & Medicaid Services (CMS) have broadened coverage for durable medical equipment, such as insulin pumps, making them cheaper and more accessible to covered patients. Such policy support favorably impacts patient uptake and prompts manufacturers to develop and serve a larger population. This synergy of government investment, facilitating policies, and investments in infrastructure serves as a significant driver for the insulin pumps market.

Restraint Factor for the Insulin Pumps Market

High Cost of Insulin Pumps and Limited Reimbursement in Developing Regions Restraining Market Growth

One of the key constrain...

According to Cognitive Market Research, the Blood Glucose Monitoring Devices Market Size will be USD XX Million in 2024 and is set to achieve a market size of USD XX Million by the end of 2033 growing at a CAGR of XX% from 2025 to 2033.

North America held largest share of xx% in the year 2024 
Europe held share of xx% in the year 2024 
Asia-Pacific held significant share of xx% in the year 2024 
South America held significant share of xx% in the year 2024
Middle East and Africa held significant share of xx% in the year 2024 

MARKET DYNAMICS: KEY DRIVERS

Rising prevalence of diabetes to surge the demand for blood glucose monitoring devices market

As a result of an increase in the incidence of diabetes globally, demand for blood glucose monitoring systems is rising sharply. The majority of individuals with diabetes, i.e., more than 90%, suffer from type 2 diabetes, which is driven by urbanisation, an ageing population, physical inactivity, and escalating prevalence rates of being overweight or obese. For example, based on national diabetes statistics report, of the U.S. adults aged 18 years and older, 97.6 million adults 18 years or older have prediabetes (38.0% of the all adult U.S. population) in 2021. As the demand for diabetes cases increases, more patients have to monitor their blood sugar levels on a regular basis in order to control their condition well. This increased demand is leading to the market for blood glucose monitoring devices as they are needed for early diagnosis, constant management, and treatment of diabetes. Also, improvements in technology and increased understanding of diabetes treatment have contributed to making the devices more affordable and easy to use, further enhancing their uptake. Healthcare systems across the globe are emphasising prevention and timely intervention, which raises the need for effective glucose monitoring solutions. In summary, the rising population with diabetes is the most important driver accelerating the growth of the blood glucose monitoring devices market. The incidence of diabetes rises with age, and elderly individuals are more likely to develop diabetes or diabetes-associated complications. When the elderly population size expands, so does the number of people at risk for diabetes, resulting in an enhanced need for blood glucose monitoring instruments.

Source: https://idf.org/about-diabetes/diabetes-facts-figures/

https://www.who.int/news/item/13-11-2024-urgent-action-needed-as-global-diabetes-cases-increase-four-fold-over-past-decades

https://www.cdc.gov/diabetes/php/data-research/

Restraints

The high prices of blood glucose monitoring devices are hampering the growth of blood glucose monitoring market.

The exorbitant price of blood glucose monitoring equipment, particularly continuous glucose monitors, is one of the major hurdles being faced by this market, which is otherwise growing steadily. Most individuals with diabetes are unable to purchase these devices because, in addition to a significant amount of money at the point of purchase, they also have recurring costs for replacement transmitters and sensors. This economic strain makes it difficult for people to regularly check their blood sugar levels, which is essential in the management of diabetes. For instance, most diabetes patients, an estimated 31%, have indicated that they do not check their glucose levels frequently because test strips are too costly. Moreover, almost half of the patients, approximately 47%, find glucose testing inconvenient, further deterring regular monitoring. These issues indicate the extent to which cost and convenience factors are constraining greater use of glucose monitoring technology. Confirming this, the American Diabetes Association (ADA) survey of 2,595 individuals with diabetes showed that one in five avoided or delayed taking up a pump or CGM, with half of these instances having a direct connection to high costs. During the pandemic, 15% of users who depend on these devices delayed replenishing their supplies, and 70% of them did so because of financial hardship. Prices show this issue as well, such as one test strip may range from 27 to 56 US cents, whereas sensors for continuous or flash glucose monitoring devices run anywhere from $88 to $107 per sensor. These expenses quickly add up, and it becomes difficult for most patients to be consistent about their use. Overall, the high expense...

The information available from this webpage comes from the National Diabetes Inpatient Audit. The National Diabetes Inpatient Audit is a snapshot audit of diabetes inpatient care. During September 2019, hospitals across England collected data on the characteristics of the hospital, including participation, staffing levels and care improvement initiatives. Wales did not participate in NaDIA 2019. Making clinical audit data transparent In his transparency and open data letter to Cabinet Ministers on 7 July 2011, the Prime Minister made a commitment to make clinical audit data available from the national audits within the National Clinical Audit and Patient Outcomes Programme. What information is being made available? National Diabetes Inpatient Audit data for 2019 is available at hospital site level for: * Audit participation and data completeness for the key fields * Measures about the process of care given to patients * Information about care outcomes and treatment. These data do not list individual patient information nor do they contain any patient identifiable data. Using and interpreting the data Data from the National Diabetes Inpatient Audit should not be looked at in isolation when assessing standards of care. Accessing the data The data are being made available on the data.gov website. Each year a data file from the National Diabetes Inpatient Audit will be made available in CSV format. Hospitals are identified by name and their national code. What period does the data cover? This report covers hospital characteristics during September 2019. The audit report was published on 13 November 2020. Historic data is available for previous audit years (2010-2013, 2015-2017) where survey questions were comparable.

NaDIA-Harms is a mandatory year-round collection of four harms that can occur to diabetic inpatients in Acute hospitals in England. The objective of NaDIA Harms is to help reduce the rates of serious inpatient harms by collecting and providing case mix adjusted benchmarked feedback to hospital trusts to inform quality improvement work.

Making clinical audit data transparent

In his transparency and open data letter to Cabinet Ministers on 7 July 2011, the Prime Minister made a commitment to make clinical audit data available from the national audits within the National Clinical Audit and Patient Outcomes Programme.

What information is being made available?

National Diabetes Inpatient Audit – Harms data for 2018 is available at national level for:

• Audit participation
• The number of harms

These data do not list individual patient information nor do they contain any patient identifiable data.

Using and interpreting the data

Data from the National Diabetes Inpatient Audit – Harms should not be looked at in isolation when assessing standards of care.

Accessing the data

The data are being made available on the data.gov website. Each year a data file from the National Diabetes Inpatient Audit - Harms will be made available in CSV format.

What period does the data cover?

The report covers impatient harms between May and October 2018. The audit report was published on 9 May 2019.